Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update

OBJECTIVE: Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies are an effective means of treating non-small cell lung cancer (NSCLC). Here, we aim to update the equivalent efficacy assessment between QL1101 and bevacizumab based on two-year follow-up data. METHODS: In total, 535 eli...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jun, Chu, Tianqing, Liu, Hongyu, Hu, Minjuan, Lou, Yuqing, Zhang, Yanwei, Gao, Zhiqiang, Zhang, Wei, Zhang, Xueyan, Wang, Huimin, Zhong, Hua, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913254/
https://www.ncbi.nlm.nih.gov/pubmed/35355930
http://dx.doi.org/10.21147/j.issn.1000-9604.2022.01.03

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913254/
https://www.ncbi.nlm.nih.gov/pubmed/35355930
http://dx.doi.org/10.21147/j.issn.1000-9604.2022.01.03

Ejemplares similares